Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab

Abstrakt

Hidradenitis suppurativa (HS) is a chronic disease characterized by inflammatory nodules, sinus tracts and scarring, predominantly in the axillae and groin areas. Adalimumab is the only approved biological therapy for the treatment of moderate to severe HS.

Despite the proven efficacy, some patients lose response to adalimumab over time or experience acute flares as it was shown in the open-label extension PIONEER trial (1). Treatment of these patients can be challenging.

Klíčová slova

• TNF-alfa antagonist
• adalimumab
• combination
• corticosteroid
• hidradenitis suppurativa
• recurrence
• therapy